Roche goes hostile, cuts Genentech bid to $42 billion
ZURICH (Reuters) - Swiss drugmaker Roche launched a surprise hostile bid for U.S. biotech group Genentech at a lower price, reflecting tougher financing conditions and a drop in Genentech shares.<div class="feedflare">
<img src="http://feeds2.feedburner.com/~f/reuters/businessNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=EsKEVU3D) <img src="http://feeds2.feedburner.com/~f/reuters/businessNews?i=KtnAcNMc" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=KtnAcNMc) <img src="http://feeds2.feedburner.com/~f/reuters/businessNews?i=ye88OlWA" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=ye88OlWA)
</div><img src="http://feeds2.feedburner.com/~r/reuters/businessNews/~4/yjpk-XvtjS4" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/yjpk-XvtjS4/idUSTRE50T1BL20090130